• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多种药物组合对人白血病细胞和正常造血前体细胞的细胞毒性比较。

Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.

作者信息

Chang T T, Gulati S, Chou T C, Colvin M, Clarkson B

出版信息

Cancer Res. 1987 Jan 1;47(1):119-22.

PMID:3466686
Abstract

The development of suitable methods for purging the malignant cells contaminating the bone marrow of patients with cancer may offer a better chance of success for autologous bone marrow transplantation. In this paper, we further describe our efforts at purging acute myelogenous leukemia cells. HL-60, a promyelocytic leukemia cell line, was used as a model. 4-Hydroperoxycyclophosphamide (4-HC), VP-16-213 (VP-16), and Adriamycin were used alone or in combination to develop the best method to purge HL-60 cells. The cytotoxicity of 29.2 micrograms/ml (100 microM) of 4-HC was 99.8 +/- 0.12% (SD) on HL-60 cells and 82.5% on colony forming units-granulocyte, macrophage. Ninety-nine % of HL-60 cells and 72.7% of colony forming units-granulocyte, macrophage were inhibited by VP-16 at a concentration of 25 micrograms/ml (42.5 microM). The cytotoxicity of 1.5 micrograms/ml (2.76 microM) of Adriamycin on HL-60 cells was 98.6 +/- 0.8% and inhibited colony forming units-granulocyte, macrophage by 50.8%. The cytotoxicity and interactions of any two drug combinations at different combination ratios and the different effect levels were quantitatively determined by median effect plot and the multiple drug effect equation (T-C. Chou and P. Talalay. Adv. Enzyme Regul. 22: 27-55, 1984). The combination of 4-HC and VP-16 at a 4-HC:VP-16 drug ratio of 1:0.342 was found to be the best for selective toxicity towards HL-60 cells and was superior to the 4-HC-Adriamycin or VP-16 Adriamycin combination for usefulness in purging bone marrow.

摘要

开发合适的方法清除癌症患者骨髓中污染的恶性细胞,可能会为自体骨髓移植带来更好的成功机会。在本文中,我们进一步描述了我们清除急性髓性白血病细胞的努力。HL-60,一种早幼粒细胞白血病细胞系,被用作模型。单独或联合使用4-氢过氧环磷酰胺(4-HC)、依托泊苷(VP-16-213,简称VP-16)和阿霉素,以开发清除HL-60细胞的最佳方法。29.2微克/毫升(100微摩尔)的4-HC对HL-60细胞的细胞毒性为99.8±0.12%(标准差),对集落形成单位-粒细胞、巨噬细胞的细胞毒性为82.5%。浓度为25微克/毫升(42.5微摩尔)的VP-16可抑制99%的HL-60细胞和72.7%的集落形成单位-粒细胞、巨噬细胞。1.5微克/毫升(2.76微摩尔)的阿霉素对HL-60细胞的细胞毒性为98.6±0.8%,并抑制集落形成单位-粒细胞、巨噬细胞50.8%。通过中位效应图和多药效应方程(T-C.周和P.塔拉莱。《酶调节进展》22:27-55,1984)定量测定了不同组合比例和不同效应水平下任意两种药物组合的细胞毒性和相互作用。发现4-HC与VP-16的药物比例为1:0.342的组合对HL-60细胞具有最佳的选择性毒性,并且在清除骨髓方面优于4-HC-阿霉素或VP-16-阿霉素组合。

相似文献

1
Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.多种药物组合对人白血病细胞和正常造血前体细胞的细胞毒性比较。
Cancer Res. 1987 Jan 1;47(1):119-22.
2
Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.通过计算机分析证明4-氢过氧环磷酰胺和依托泊苷对人早幼粒细胞白血病细胞系(HL-60)的协同作用。
Cancer Res. 1985 Jun;45(6):2434-9.
3
In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.VP-16-213(依托泊苷)和氮芥的体外细胞毒性:对肿瘤细胞具有激动作用,但对正常人骨髓祖细胞无此作用。
Exp Hematol. 1990 Oct;18(9):1008-12.
4
Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.急性髓细胞白血病患者外周血干细胞采集中微小残留病的药理学清除:临床前研究
Exp Hematol. 1997 Nov;25(12):1261-9.
5
Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
Exp Hematol. 1990 Dec;18(11):1193-8.
6
Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.依托泊苷联合环孢素在小鼠模型中用于清除骨髓中多药耐药白血病细胞的研究。
Exp Hematol. 1992 Oct;20(9):1048-54.
7
Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.马磷酰胺(Asta-Z 7654)与依托泊苷(VP-16-213)联合用于净化白血病自体骨髓的临床前研究。
Exp Hematol. 1988 Feb;16(2):97-101.
8
Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
Blood. 1991 Apr 15;77(8):1829-36.
9
Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.4-氢过氧环磷酰胺(4-HC)与顺铂联合用于自体骨髓移植中的骨髓净化:最新进展
Prog Clin Biol Res. 1990;333:57-68.
10
In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.人造血祖细胞对4-氢过氧环磷酰胺的体外敏感性
Exp Hematol. 1993 Dec;21(13):1663-7.

引用本文的文献

1
TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.用于中度风险复发性儿童急性淋巴细胞白血病的创伤性脑损伤、依托泊苷和环磷酰胺预处理
Int J Hematol. 2024 Apr;119(4):450-458. doi: 10.1007/s12185-024-03710-6. Epub 2024 Jan 25.
2
Combination antifungal therapy.联合抗真菌治疗。
Antimicrob Agents Chemother. 2004 Mar;48(3):693-715. doi: 10.1128/AAC.48.3.693-715.2004.
3
Interaction between cisplatin, 5-fluorouracil and vincristine on human hepatoma cell line (7721).
顺铂、5-氟尿嘧啶和长春新碱对人肝癌细胞系(7721)的相互作用。
World J Gastroenterol. 1998 Oct;4(5):418-420. doi: 10.3748/wjg.v4.i5.418.
4
Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.几种抗肿瘤药物及其他药剂与强效烷基化剂阿多来新的协同和相加组合。
Cancer Chemother Pharmacol. 1995;35(6):471-82. doi: 10.1007/BF00686831.
5
The effect of high energy shock waves (HESW) on human bone marrow.高能冲击波(HESW)对人骨髓的影响。
Urol Res. 1988;16(6):427-9. doi: 10.1007/BF00280023.
6
Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562.槲皮素增强白消安对人白血病细胞系K562的抗增殖作用。
Br J Cancer. 1989 Mar;59(3):347-8. doi: 10.1038/bjc.1989.68.
7
Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.
Cancer Chemother Pharmacol. 1990;26(5):345-51. doi: 10.1007/BF02897291.
8
Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.依托泊苷。对其药效学和药代动力学特性以及在癌症联合化疗中的治疗潜力的综述。
Drugs. 1990 Mar;39(3):438-90. doi: 10.2165/00003495-199039030-00008.
9
Relationships between various uses of antineoplastic drug-interaction terms.抗肿瘤药物相互作用术语的各种用法之间的关系。
Cancer Chemother Pharmacol. 1992;31(2):111-7. doi: 10.1007/BF00685096.